6293-20-5 Usage
Description
ETHYL UREIDOACETATE is an organic compound that serves as an intermediate in the synthesis of various pharmaceuticals and chemical compounds. It is characterized by its urea and ester functional groups, which contribute to its reactivity and potential applications in chemical reactions.
Uses
Used in Pharmaceutical Industry:
ETHYL UREIDOACETATE is used as a chemical intermediate for the synthesis of benzoylhydantoic acids by reacting with benzoic acids. This reaction is crucial in the preparation of various pharmaceutical compounds, as benzoylhydantoic acids are key components in the development of drugs with therapeutic properties.
Used in Chemical Synthesis:
In the field of chemical synthesis, ETHYL UREIDOACETATE is utilized as a versatile building block for the creation of a wide range of chemical compounds. Its urea and ester functional groups make it a valuable precursor in the synthesis of various organic molecules, including those with potential applications in materials science, agrochemicals, and other industries.
Synthesis Reference(s)
Journal of the American Chemical Society, 72, p. 2880, 1950 DOI: 10.1021/ja01163a019
Check Digit Verification of cas no
The CAS Registry Mumber 6293-20-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,2,9 and 3 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 6293-20:
(6*6)+(5*2)+(4*9)+(3*3)+(2*2)+(1*0)=95
95 % 10 = 5
So 6293-20-5 is a valid CAS Registry Number.
6293-20-5Relevant articles and documents
Tolman et al.
, p. 243,246 (1968)
Highly selective aldose reductase inhibitors. 1. 3-(Arylalkyl)-2,4,5- trioxoimidazolidine-1-acetic acids
Ishii,Kotani,Nagaki,Shibayama,Toyomaki,Okukado,Ienaga,Okamoto
, p. 1924 - 1927 (2007/10/03)
A series of 3-(arylalkyl)-2,4,5-trioxoimidazolidine-1-acetic acids (1) was prepared and tested for aldose reductase (AR) and aldehyde reductase (ALR) inhibitory activities. These compounds showed strong inhibitory activity against AR without significant inhibitory activity for ALR. The ratio of IC50(ALR)IC50(AR) was > 1000 in some compounds. On the basis of pharmacological tests such as the recovery of reduced motor nerve conduction velocity and toxicological profile, 3-(3-nitrobenzyl)-2,4,5- trioxoimidazolidine-1-acetic acid (NZ-314) was selected as the candidate for clinical development.
Description of the preparation of hydantoin and 2-thiohydantoin
Thielemann
, p. 174 - 174 (2007/10/04)
-
